Recursion Apr 29, 2026 Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 - The Manila Times
Recursion Apr 29, 2026 Patient advocate offers Recursion a powerful reason to keep going in rare disease - BioSpace
Recursion Apr 26, 2026 Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities - Yahoo Finance
Recursion Apr 24, 2026 Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com Canada
Recursion Apr 24, 2026 Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
Recursion Apr 24, 2026 [SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
Recursion Apr 24, 2026 AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st
Recursion Apr 20, 2026 Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note - MSN
Recursion Apr 19, 2026 Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership - Yahoo Finance UK
Recursion Apr 16, 2026 Is Recursion Pharmaceuticals (RXRX) Turning Conference Spotlights Into a Durable AI Drug Discovery Edge? - simplywall.st
Recursion Apr 15, 2026 Recursion CEO outlines AI drug discovery strategy in Morgan Stanley webcast - Investing.com
Recursion Apr 11, 2026 Recursion Pharmaceuticals Stock (RXRX) Opinions on Upcoming Earnings and AI Developments - Quiver Quantitative
Recursion Apr 10, 2026 Recursion And Citeline Deepen AI Trial Data Tie For RXRX Investors - Yahoo Finance
Recursion Mar 31, 2026 Citeline expands partnership with Recursion for clinical trials - Investing.com